BofA analyst Tazeen Ahmad downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Cautious Hold Rating on Sutro Biopharma Amid Strategic Shift and Restructuring
- Sutro Biopharma’s Strategic Shift: Hold Rating Amid Reprioritization and Financial Restructuring
- Sutro Biopharma downgraded to Neutral from Outperform at Wedbush
- Sutro Biopharma downgraded to Market Perform from Outperform at Citizens JMP
- Sutro Biopharma Announces Strategic Review and Leadership Change